FDA panel to review broader use for heart failure device
This article was originally published in Clinica
Executive Summary
The US FDA has scheduled for July 28, an advisory panel meeting to review an application to expand the use of Guidant's cardiac resynchronisation therapy defibrillators (CRT-D) for heart failure patients.